Bal Pharma Reports Declining Financial Metrics Amidst Challenging Market Conditions in June'25

Bal Pharma, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results indicate a challenging period for the company, with notable declines across several key financial metrics.
Net sales for the quarter reached Rs 65.87 crore, reflecting a year-on-year decrease. This marks the lowest sales figure recorded in the past five quarters, suggesting a concerning trend in revenue generation. Additionally, the operating profit, measured as PBDIT, also hit a low of Rs 6.06 crore, further emphasizing the difficulties faced by the company in maintaining profitability.

The company's ability to manage its interest payments has come under scrutiny, as evidenced by an operating profit to interest ratio of 1.50 times, the lowest in the last five quarters. Profit After Tax (PAT) has also seen a decline, reported at Rs 0.21 crore, which is significantly lower than previous periods.

In light of these developments, Bal Pharma has experienced an adjustment in its evaluation, with its score reflecting the current financial landscape.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.